Methods for treating cancer by regulation of tumor necrosis factor-alpha
View Patent ↗The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.
1. A method of treating a cancer, comprising:
a) administering a TNFα- inducing amount of an IL-32 protein encoded by a nucleic acid comprising the sequence set forth in SEQ ID NO:15 to a subject comprising one or more cancer cells, wherein said subject exhibits at least one symptom of said cancer; and
b) ameliorating said at least one symptom of said cancer by inducing apoptosis in said one or more cancer cells by said induced TNF-α expression.
2. The method of claim 1 , wherein said IL-32 protein is a recombinant protein.
3. The method of claim 1 , wherein said providing further comprises a pharmaceutically acceptable carrier.
4. The method of claim 1 , wherein said administering is parenteral.
5. The method of claim 3 , wherein said pharmaceutically acceptable carrier comprises a liposome.
6. A method of treating a cancer, comprising:
a) administering a TNFα- inducing amount of an IL-32 protein encoded by SEQ ID NO:3 to a subject comprising one or more cancer cells, wherein said subject exhibits at least one symptom of said cancer; and
b) ameliorating said at least one symptom of said cancer by inducing apoptosis in said one or more cancer cells by said induced TNF-α expression.
7. The method of claim 6 , wherein said IL-32 protein is a recombinant protein.
8. The method of claim 6 , wherein said providing further comprises a pharmaceutically acceptable carrier.
9. The method of claim 6 , wherein said administering is parenteral.
10. The method of claim 8 , wherein said pharmaceutically acceptable carrier comprises a liposome.
11. A method of treating a cancer, comprising:
a) administering a TNFα- inducing amount of an IL-32 protein encoded by SEQ ID NO:6 to a subject comprising one or more cancer cells, wherein said subject exhibits at least one symptom of said cancer; and
b) ameliorating said at least one symptom of said cancer by inducing apoptosis in said one or more cancer cells by said induced TNF-α expression.
12. The method of claim 11 , wherein said IL-32 protein is a recombinant protein.
13. The method of claim 11 , wherein said providing further comprises a pharmaceutically acceptable carrier.
14. The method of claim 11 , wherein said administering is parenteral.
15. The method of claim 13 , wherein said pharmaceutically acceptable carrier comprises a liposome.